Abstract
Immunoglobulin G1 (IgG1), a subclass of human serum antibodies, is the most widely used scaffold for developing monoclonal antibodies to treat human diseases. The composition of asparagine(N)297-linked glycans can modulate the binding affinity of IgG1 Fc to Fc γ receptors, but it is unclear how the structural modifications of N-glycan termini, which are distal from the binding interface, contribute to the affinity. Through atomistic molecular dynamics simulations of a series of sequentially truncated high-mannose IgG1 Fc glycoforms, we found that the C′E loop and the Cγ2-Cγ3 orientation are highly dynamic, and changes in N-glycan composition alter their conformational ensembles. High-mannose glycoform preferentially samples conformations that are more competent to FcγRIIIa binding, compared to the truncated glycoforms, suggesting a role of IgG1 Fc N-glycan in optimizing the interface with the Fc receptor for efficient binding. The trajectory analyses also reveal that the N-glycan has large amplitude motions and the carbohydrate moiety interconverts between Fc-bound and unbound forms, enabling enzymatic modification of the glycan termini.
Introduction
Antibody, also known as immunoglobulin (Ig), is produced by B cells and specifically binds to invading pathogens in the blood to stop them from functioning. Some antibodies play their role simply through the binding of their antigen-binding Fab domains to the target epitopes to block or induce signal transduction. On the other hand, many other antibodies recognize the antigen and then recruit circulating lymphoid and myeloid cells to kill the target through antibody-mediated effector functions (i.e., complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis)1–3. Aside from these natural functions, its role as a bridge between pathogens and the immune system has made antibodies the fastest growing class of new drugs to treat a wide range of human diseases3–5.
Immunoglobulin G1 (IgG1) is a subclass of human serum antibodies and is the most widely used platform for developing therapeutic monoclonal antibodies6. The antibody-mediated effector functions require binding of the crystallizable fragment (Fc) of IgG1 to Fc γ receptors (FcγRs) that are expressed on the surface of recruited cells. IgG1 Fc is a symmetric homodimer comprised of the C-terminal half of Ig heavy-chain polypeptides, and each consists of an N-terminal Cγ2 domain and a C-terminal Cγ3 domain (Fig. 1A). The homodimer is formed by disulfide bonds between the N-terminal hinge regions in the Cγ2 domains and non-bonded interactions between the Cγ3 domains.
Glycosylation, the most common post-translational modification, and its effects on protein structure and function have been a topic of interest for many years7–10. Many experiments have provided evidences that glycosylation can alter thermodynamic, kinetic, and structural features of proteins, resulting in modulation of a broad array of biological processes such as protein folding, stability, oligomerization, quality control, trafficking, enzyme activity, and host cell-surface interactions11–14. We previously performed a Protein Data Bank (PDB) survey and a molecular dynamics (MD) simulation study to investigate the common effects of asparagine (N)-linked glycans on protein structure and dynamics. Our study indicates that the glycosylation does not induce significant changes in protein structure, but lowers structural fluctuation8. Given a specific protein, however, effects by glycosylation become more sophisticated. In the case of IgG1, the binding of its Fc domain to FcγRs requires the post-translational modification of the Fc region with an N-glycan at Asn 29715,16. In addition, composition changes in the IgG1 Fc glycans are also known to affect the binding affinity17–20.
The crystal structures of IgG1 Fc in complex with an Fc receptor, FcγRIIIa, have revealed that a significantly better binding affinity of afucosylated IgG1 Fc to FcγRIIIa results from additional carbohydrate-carbohydrate interactions between the Fc and receptor glycans21. Particularly, it is noteworthy that changes in the N-glycan non-reducing termini, which are distal from the binding interface between IgG1 Fc and FcγRs (Fig. 1), can modulate the binding affinity. However, a molecular-level understanding on how the structural modifications of N-glycan termini contribute to changes in Fc:FcγR binding affinity remains enigmatic. In addition to the biological significance of elucidating the role of N-glycans in Fc binding to FcγRs, proper N-glycan remodeling is also required for the development of next generation IgG1-based antibodies through Fc N-glycan optimization22–24.
To explore both challenges (antibody biology and engineering), we investigated the impacts of different N-glycan compositions on the structure and dynamics of IgG1 Fc using atomistic MD simulations of a series of sequentially truncated high-mannose IgG1 Fc glycoforms (Fig. 1B): (1) Fc with high-mannose N-glycans (Man8GlcNAc2, Fc-Man8), (2) Fc with five mannoses (Man5GlcNAc2, Fc-Man5), (3) Fc with a single core N-acetylglucosamine (Fc-GlcNAc), (4) aglycosylated Fc (Fc-N297Q), and (5) Fc with an asymmetric glycoform (Fc-Man8/N297Q). These simulations collectively reveal that IgG1 Fc is highly dynamic and structural changes in glycan termini modulate a conformational ensemble of IgG1 Fc. High-mannose glycoform preferentially samples C′E loop conformation and Cγ2-Cγ3 orientation that are most relevant to FcγRIIIa binding, compared to the truncated glycoforms. We also report large amplitude motions of N-glycans, causing most carbohydrate moieties to be detached from the Fc polypeptide surface and making them accessible for enzymatic modifications of the glycan termini.
Results
Glycans interconvert between Fc-bound and unbound forms
To characterize the dynamics of Fc N-glycans during the simulations, we measured minimum distances between any heavy atoms of the terminal residues of each glycan (e.g., mannoses 6, 7, and 10 in Fig. 1B Fc-Man8) and any protein heavy atoms as a function of simulation time (Fig. 2A). Many peaks with distances > 4.5 Å are shown in the time-series, indicating that the glycan termini have no contact with the Fc surface and they are exposed to the bulk water (Fig. 2B). The sharp minimum distance peaks (i.e., minimum distance > 9 Å) correspond to the cases where most glycan residues are detached from the Fc surface. The representative structures are illustrated in Fig. 2C. Such large amplitude motions are also observed for Fc-Man5 (Fig. 3A). We performed an additional 2-μs simulation as an independent replica for Fc-Man8 (Fc-Man8_R) to further examine the large-amplitude glycan motions. In this simulation, however, the minimum distance time-series (Fig. 3B) do not show the complete detachment of either glycan. Collectively, our simulations indicate that Fc glycans have highly dynamic motions enabling interconversion between Fc-bound and unbound conformational states, but such motions are stochastic. Supplementary Video S1–S6 show 2-µs simulation movies for five systems (Fc-Man8, Fc-Man5, Fc-GlcNAc, Fc-N297Q, and Fc-Man8/N297Q) and the independent replica of Fc-Man8 (Fc-Man8_R).
Highly fluctuating C′E loop is an innate property of IgG1 Fc
To investigate the effects of N-glycan composition on the local structure and dynamics of IgG1 Fc, we focus our analyses on a structural element in the Fc region, the so-called C′E loop (Gln295 –Tyr – Asn297 – Ser – Thr299; Fig. 4). The C′E loop not only contains the N-glycosylation site, but also is a primary interface involved in intermolecular interactions with FcγRIIIa (Figure S1A). Other studies have reported that the binding affinity of IgG1 Fc to FcγRIIIa is attributed to specific conformations and/or structural fluctuations of the C′E loop25,26. The initial simulation structures have a C′E loop conformation very similar to that in the crystal structure of IgG1 Fc:FcγRIIIa complex (PDB: 3sgk) (Fig. 4B and Figure S1B).
Figure 5 shows the time-series of root-mean-square deviations (RMSDs) of the C′E loop with respect to the initial structure. To better understand a relationship between the RMSD profiles and the C′E loop conformations, we compared representative MD snapshots with the initial structures. We first examined the C′E loop conformations where N-glycan is fully detached from the Fc surface (i.e., snapshots 1 and 2 for Fc-Man8 and 3 and 5 for Fc-Man5; also see Fig. 2A and Fig. 3A for the minimum distance plots). The structural comparisons in Fig. 6 indicate that large conformational changes of C′E loop (with the RMSDs of 6.12 Å, 7.61 Å, and 8.32 Å for snapshots 1, 3, and 5, respectively) together with unstructured short C′ β-strand (Figure S2) are commonly accompanied with the glycan detachment. For the future reference, these C′E loop conformations are classified into an “unstructured state”.
In contrast to snapshots 1, 3, and 5, snapshot 2 has a relatively low RMSD (3.49 Å) and structured C′ strand, but the C′E loop has a less bent conformation, facing outside the cavity between the Fc polypeptide monomers. So, this conformation is classified into an “outward-facing state”. This structure also indicates that disordered C′ strand is not a necessary prerequisite for N-glycan to be detached from the Fc surface or a consequence of the glycan detachment. We then examined the snapshot 4 of Fc-Man5 in which no glycan detachment is observed in Fc polypeptide chain A (Fig. 3A), but the C′E loop RMSD is notably high (9.84 Å). In this case, the C′ strand is well ordered, but the C′E loop and its linked strands bends towards the Fc cavity. This conformation is classified into an “inward-facing state”.
Based on these classifications, we examined if the C′E loop conformations sampled by aglycosylated form are different from those by glycosylated forms. To address this, three representative snapshots 6, 7, and 8 (marked in Fig. 5) are shown in Fig. 7A. The structural comparisons indicate that aglycosylated Fc sampled all different conformational states (i.e., snapshot 6: inward-facing state with an RMSD of 7.52 Å, snapshot 7: outward-facing state with an RMSD of 3.50 Å, and snapshot 8: unstructured state with an RMSD of 10.31 Å) in Fc-Man8 and Fc-Man5. The C′E loop conformational fluctuations between the outward- and inward-facing states are also clearly observed in the aglycosylated polypeptide in Fc-Man8/N297Q (Fig. 7B; snapshots 9 and 10 marked in Fig. 5). Collectively, our simulations indicate that the C′E loop conformation varies and the structural fluctuation results from innate dynamics of the Fc polypeptides, regardless of the existence of N-glycans.
N-glycan composition alters an ensemble of C′E loop conformations
To characterize a difference in C′E loop conformations in between different Fc glycoforms, we analyzed the trajectories where C′E loop conformations are not related to the glycan detachment from the protein surface and unstructured C′ strand (i.e., the loop has relatively low RMSDs and remain stable over the entire simulation time). These trajectories are Fc polypeptide chains A and B in Fc-Man8_R, Fc-GlcNAc, and Fc-Man8/N297Q and chain A in Fc-N297Q. We calculated their average RMSDs during the last 1.5 μs and the values are 2.68 ± 0.76 Å (chain A) and 3.04±1.01 Å (chain B) in Fc-Man8_R, 3.40±0.67 Å (chain A) and 4.11±0.48 Å (chain B) in Fc-GlcNAc, 4.42±0.83 Å (chain A) in Fc-N297Q, and 3.13±0.68 Å (chain A) and 4.66±0.97 Å (chain B) in Fc-Man8/N297Q. The data show that, although the differences are subtle, the C′E loop in high-mannose IgG1 Fc glycoform least deviates from the initial structure and on average is most similar to the crystal structure of IgG1 Fc:FcγRIIIa complex. The structural deviation of the C′E loop becomes larger as the N-glycans are more truncated. It is noted that the asymmetric system, Fc-Man8/N297Q has clearly separated RMSD profiles between high-mannose glycosylated and aglycosylated polypeptide (Fig. 5). The representative snapshots taken at simulation time 9 and 10 are illustrated in Fig. 7B to show the difference in C′E loop conformations between the Fc polypeptides.
The crystal structure of IgG1 Fc in complex with FcγRIIIa reveals that the first GlcNAc (GlcNAc1) of Fc forms direct hydrogen bonds with the first two GlcNAc units of the receptor, indicating significant contributions to the protein-protein binding affinity21 (Figure S1A). Our MD initial structures also have a conserved GlcNAc1 conformation as in the IgG1 Fc:FcγRIIIa crystal structure (Figure S1B). We measured the RMSD time-series of GlcNAc1 and calculated the average RMSD during the last 1.5 μs (Fig. 8). The values are 3.85±1.32 Å and 2.26±0.68 Å for Fc-Man8_R and 4.37±0.66 Å and 6.15±0.46 Å for Fc-GlcNAc, showing that the conformational changes of the C′E loop also lead to structural and orientational deviation of GlcNAc1. Taken together, the results suggest that a high-mannose glycan stabilizes the C′E loop and the GlcNAc1 into a conformation that is more competent to Fc receptor binding, compared to the truncated ones.
N-glycan composition alters a conformational ensemble of Cγ2-Cγ3 orientation
We examined if different N-glycan compositions affect the global motions of IgG1 Fc. We assigned FcγRIIIa-interacting Fc residues based on the IgG1 Fc/FcγRIIIa crystal structure and then measured the distances (D AB) between the geometric center of the chain A residues and that of the chain B residues. Their probability distributions calculated using the last 1.5-μs trajectories show that high mannose-containing systems (Fc-Man8 and Fc-Man8_R) sample significantly more Fc conformations whose D AB are comparable to that in the crystal structure, whereas the D AB in other systems are all biased to the smaller distance (Fig. 9).
We also measured angles (θ) and dihedral angles (ϕ) between Cγ2 and Cγ3 in each Fc chain and between Cγ3 A and Cγ3B to investigate global conformational changes in IgG1 Fc; Figure S3 shows the points used to define θ and ϕ, which are based on Frank et al.’s study27. As shown in Fig. 10, the intra-chain Cγ2-Cγ3 motions are highly dynamic (e.g., θ = 68.0° to 104.0° and ϕ = −51.4° to 17.7° for Fc-Man8 chain A), while the inter-chain Cγ3-Cγ3 motions (Figure S4) were much more restricted (e.g., θ = 79.3° to 91.7° and ϕ = 105.7° to 127.4° for Fc-Man8), indicating stable inter-Cγ3 domain interactions to form a homodimer. It appears that the Cγ2-Cγ3 domain orientations do not show a significant correlation with the detachment of N-glycans from the Fc surface (Figure S5). A distinguishable feature from the distribution plots is that the ranges of Cγ2-Cγ3 θ and ϕ become markedly broader when Fc polypeptide chain is aglycosylated (i.e., chains A and B in Fc-N297Q and chain B in Fc-Man8/N297Q), suggesting that even the presence of a single monosaccharide can confer significant impact on Fc dynamics.
Concluding Discussion
The data presented herein clearly show that the glycosylated local region (i.e., C′E loop) and Cγ2-Cγ3 domain orientation of IgG1 Fc are highly dynamic and different N-glycan compositions alter their structural ensembles. High-mannose glycoform preferentially samples the C′E loop conformations and the Cγ2-Cγ3 orientations that are more competent to FcγRIIIa binding, compared to truncated glycoforms. This strongly suggests that in addition to its direct interactions with the Fc receptors, a role of IgG1 Fc N-glycan is to optimize the interface with the Fc receptor for efficient binding. Our simulations also show that Fc N-glycan has dramatic motions in which the carbohydrate moiety is detached from Fc polypeptide surface, enabling enzymatic modification of the glycan termini.
Okbazghi et al. recently produced four different IgG1 Fc glycoforms (Fc-Man8, Fc-Man5, Fc-GlcNAc, and Fc-N297Q) as a model system and evaluated their binding affinity to FcγRIIIa17. Fc-Man8 and Fc-Man5 have a comparable biding affinity to the receptor (K D ~ 26 nM for Fc-Man8 and ~32 nM for Fc-Man5), while Fc-GlcNAc has weak affinity (K D ~ 995 nM), and Fc-N297Q does not show measurable affinity. Intriguingly, their experimental measurements correlate with the average C′E loop RMSDs from our simulations (i.e., the lower the average RMSD is, the higher the binding affinity is), suggesting that preorganized C′E loop conformation is a determinant of high binding affinity of IgG1 Fc to FcγRIIIa. As an additional experimental support, Subedi and Barb recently reported that the primary role of IgG1 Fc N-glycan is to restrict the C′E loop conformation for optimal binding affinity based on their solution nuclear magnetic resonance (NMR) spectroscopy data26. It is expected that the weakest affinity of aglycosylated form is also attributed to the absence of GlcNAc1 that is a key moiety for FcγRIIIa interactions.
The NMR study by Subedi and Barb also reported that the Cγ2-Cγ3 domain orientation of glycosylated Fc is indistinguishable from aglycosylated Fc, indicating that N-glycans little affect the global conformation of IgG1 Fc and, as a result, do not predominantly contribute to binding affinity to FcγRIIIa26. On the other hand, Borrok et al. found that the aglycosylated Fc has a larger radius of gyration (R g) than glycosylated Fc by small-angle X-ray scattering (SAXS), indicating that the aglycosylated form has more open Fc conformations28. Our simulations show that high-mannose and aglycosylated Fc have a comparable R g (25.86±0.37 Å for Fc-Man8 and 25.60±0.58 Å for Fc-N297Q), but the distributions of Cγ2-Cγ3 angle and dihedral angle are markedly broad in the aglycosylated form, indicating high fluctuation of Cγ2-Cγ3 orientation (Fig. 9 and Fig. 10). Interestingly, the conformations of high-mannose glycoforms are more populated in a state where Fc binding interfaces with FcγRIIIa are more preorganized, whereas the distribution in the aglycosylated form is biased to a more closed binding interface state (Fig. 9). This suggests a possible role of N-glycan in maintaining IgG1 Fc in the conformation for optimal binding to the Fc receptors, even though it is hard to estimate how dominantly this effect contributes to the binding affinity.
Our simulations show great amplitude motions of Fc N-glycan in which most of the glycan residues are detached from Fc surface, exposing the glycan termini to the bulk solvent for enzymatic modification. This is consistent with studies on Fc glycan accessibility and NMR dynamics that Fc glycans have two distinct states: one with the glycan termini sequestered by interactions with the polypeptide surface and the other with glycan termini free from the glycan-polypeptide interactions and exposed to the bulk solution29,30. Frank et al. performed a 200-ns MD simulation study for a complex-type biantennary glycan linked to IgG1 Fc, reporting exchanging motions of the glycans between bound and unbound conformations. However, their simulations did not provide evidence of glycan’s excursion from the Fc cavity for enzyme modification of glycan termini27. Our 2-μs simulations demonstrate the large-amplitude events at the molecule level.
Our MD simulations offer new insights into the motions of Fc glycans and the structure and dynamics of IgG1 Fc to better understand biological roles of Fc glycan. The data also highlight that our analyses (e.g., changes in C′E loop conformation and Cγ2-Cγ3 orientation) can be used as effective descriptors to predict binding affinity of IgG1 Fc to its receptors and eventually could guide engineering of IgG1-based antibodies through Fc N-glycan optimization for better efficiency.
Methods
An initial structure of IgG1 Fc was generated using PDB:2wah because this IgG1 Fc has high mannose-type N-glycans and an open conformation. The original N-glycans consists nine Mannoses and two N-acetylglucosamines, but many residues are missing in the crystal structure (glycan residue 10 in chain A and residues 4–10 in chain B; see Fig. 1B for glycan residue numbering). To generate high mannose-type N-glycans (Fc-Man8), we copied chain A glycan residue 6 for chain A glycan residue 10 and then the glycan A residues 4–10 for chain B glycan residues 4–10. Fc-Man5, Fc-GlcNAc, Fc-N297Q, and Fc/Man8/N297Q were generated by removing glycan residues or mutating N297 to Q297.
To generate simulation input files for each system, we used Quick MD Simulator integrated with Glycan Reader 31 at the CHARMM-GUI website (www.charmm-gui.org)32. The TIP3P model was used for explicit water molecules. The cubic system size was determined to have at least 15 Å from the protein in each axis, and 150 mM KCl was added. The system information is given in Table S1. The CHARMM36 force field33–35 was used for the proteins and carbohydrates. All calculations were performed at 300 K. The particle mesh Ewald algorithm36 was applied to calculate electrostatic forces, and the van der Waals interactions were smoothly switched off at 10–12 Å by a force-switching function37. A time step of 2 fs was used in all simulations. Each system was shortly equilibrated in constant particle number, volume, and temperature (NVT) condition with restraints using CHARMM38. To assure gradual equilibration of the system, positional restraints for backbone and side chain heavy atoms were applied and the restraint forces were gradually reduced during the equilibration. Additional dihedral angle restraints were applied to restrain all the sugar rings to the pertinent chair conformation. NAMD39 was used for additional 10-ns constant particle number, pressure, and temperature (NPT) equilibration without restraints for each system. For NAMD NPT simulation, Langevin coupling coefficient was set to 1 ps−1 and a Nosé-Hoover Langevin-piston40,41 was used to maintain constant pressure (1 bar) with a piston period of 50 fs and a piston decay of 25 fs.
Each system was further simulated for 2 μs on Anton42 using the CHARMM36 force field. The NVT ensemble was used with the temperature maintained at 300 K using the Nosé-Hoover method. The time step was 2 fs and trajectories were saved every 240 ps. The short-range forces and long-range electrostatics were evaluated every 2 fs and 6 fs, respectively. The short-range nonbonded and electrostatic interactions were calculated with a cutoff of 9.52 Å. The long-range electrostatic interactions were calculated using the k-Gaussian Split Ewald method43. SHAKE was used to constrain all bonds involving hydrogen atoms. Convergence of the Anton simulations for all systems was checked through the comparison of average RMSD during the first and second halves of the simulations for IgG1 Fc, C′E loop, and glycans (Table S2).
Electronic supplementary material
Acknowledgements
This work was supported by NSF DBI-1707207 and XSEDE MCB070009. Anton computer time was provided by the National Center for Multiscale Modeling of Biological Systems (MMBioS) through Grant P41GM103712-S1 from the National Institutes of Health and the Pittsburgh Supercomputing Center (PSC). The Anton machine at PSC was generously made available by D.E. Shaw Research. We thank Seonghoon Kim for preforming Anton simulations and Adam W. Barb for careful reading of the manuscript and helpful comments.
Author Contributions
H.S.L. and W.I. designed the study and experiments. H.S.L. performed the experiments. H.S.L. and W.I. prepared manuscript.
Competing Interests
The authors declare that they have no competing interests.
Footnotes
Electronic supplementary material
Supplementary information accompanies this paper at 10.1038/s41598-017-12830-5.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Stevenson GT. Three major uncertainties in the antibody therapy of cancer. Haematologica. 2014;99:1538–1546. doi: 10.3324/haematol.2013.084640. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 2008;7:538–547. doi: 10.1016/S1474-4422(08)70110-8. [DOI] [PubMed] [Google Scholar]
- 3.Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 2010;9:325–338. doi: 10.1038/nrd3003. [DOI] [PubMed] [Google Scholar]
- 4.Lonberg N. Human antibodies from transgenic animals. Nat. Biotechnol. 2005;23:1117–1125. doi: 10.1038/nbt1135. [DOI] [PubMed] [Google Scholar]
- 5.Waldmann TA. Immunotherapy: past, present and future. Nat. Med. 2003;9:269–277. doi: 10.1038/nm0303-269. [DOI] [PubMed] [Google Scholar]
- 6.Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 2010;9:767–774. doi: 10.1038/nrd3229. [DOI] [PubMed] [Google Scholar]
- 7.Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 2010;10:345–352. doi: 10.1038/nri2747. [DOI] [PubMed] [Google Scholar]
- 8.Lee, H. S., Qi, Y. & Im, W. Effects of N-glycosylation on protein conformation and dynamics: Protein Data Bank analysis and molecular dynamics simulation study. Sci. Rep. 5, 8926 (2015). [DOI] [PMC free article] [PubMed]
- 9.Qi YF, Jo S, Im W. Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies. Glycobiology. 2016;26:251–260. doi: 10.1093/glycob/cwv101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Yang M, Huang J, Simon R, Wang LX, MacKerell AD., Jr Conformational Heterogeneity of the HIV Envelope Glycan Shield. Sci. Rep. 2017;7:4435. doi: 10.1038/s41598-017-04532-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Hanson SR, et al. The core trisaccharide of an N-linked glycoprotein intrinsically accelerates folding and enhances stability. Proc. Natl. Acad. Sci. USA. 2009;106:3131–3136. doi: 10.1073/pnas.0810318105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Bosques CJ, Imperiali B. The interplay of glycosylation and disulfide formation influences fibrillization in a prion protein fragment. Proc. Natl. Acad. Sci. USA. 2003;100:7593–7598. doi: 10.1073/pnas.1232504100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Imberty A, Varrot A. Microbial recognition of human cell surface glycoconjugates. Curr. Opin. Struct. Biol. 2008;18:567–576. doi: 10.1016/j.sbi.2008.08.001. [DOI] [PubMed] [Google Scholar]
- 14.Skropeta D. The effect of individual N-glycans on enzyme activity. Bioorg. Med. Chem. 2009;17:2645–2653. doi: 10.1016/j.bmc.2009.02.037. [DOI] [PubMed] [Google Scholar]
- 15.Lux A, Yu X, Scanlan CN, Nimmerjahn F. Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. J. Immunol. 2013;190:4315–4323. doi: 10.4049/jimmunol.1200501. [DOI] [PubMed] [Google Scholar]
- 16.Nose M, Wigzell H. Biological significance of carbohydrate chains on monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 1983;80:6632–6636. doi: 10.1073/pnas.80.21.6632. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Okbazghi SZ, et al. Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis. J. Pharm. Sci. 2016;105:559–574. doi: 10.1016/j.xphs.2015.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Subedi GP, Barb AW. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc gamma receptor. MAbs. 2016;8:1512–1524. doi: 10.1080/19420862.2016.1218586. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Yamaguchi Y, et al. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim. Biophys. Acta. 2006;1760:693–700. doi: 10.1016/j.bbagen.2005.10.002. [DOI] [PubMed] [Google Scholar]
- 20.Shields RL, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002;277:26733–26740. doi: 10.1074/jbc.M202069200. [DOI] [PubMed] [Google Scholar]
- 21.Ferrara C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. USA. 2011;108:12669–12674. doi: 10.1073/pnas.1108455108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Nimmerjahn F, Ravetch JV. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun. 2012;12:13. [PMC free article] [PubMed] [Google Scholar]
- 23.Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr. Opin. Biotechnol. 2009;20:685–691. doi: 10.1016/j.copbio.2009.10.011. [DOI] [PubMed] [Google Scholar]
- 24.Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J. Hematol. Oncol. 2013;6:1. doi: 10.1186/1756-8722-6-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Matsumiya S, et al. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J. Mol. Biol. 2007;368:767–779. doi: 10.1016/j.jmb.2007.02.034. [DOI] [PubMed] [Google Scholar]
- 26.Subedi GP, Barb AW. The Structural Role of Antibody N-Glycosylation in Receptor Interactions. Structure. 2015;23:1573–1583. doi: 10.1016/j.str.2015.06.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Frank M, Walker RC, Lanzilotta WN, Prestegard JH, Barb AW. Immunoglobulin G1 Fc domain motions: implications for Fc engineering. J. Mol. Biol. 2014;426:1799–1811. doi: 10.1016/j.jmb.2014.01.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Borrok MJ, Jung ST, Kang TH, Monzingo AF, Georgiou G. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem. Biol. 2012;7:1596–1602. doi: 10.1021/cb300130k. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Barb AW, et al. NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry. 2012;51:4618–4626. doi: 10.1021/bi300319q. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Barb AW, Prestegard JH. NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat. Chem. Biol. 2011;7:147–153. doi: 10.1038/nchembio.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Jo S, Song KC, Desaire H, MacKerell AD, Jr, Im W. Glycan Reader: automated sugar identification and simulation preparation for carbohydrates and glycoproteins. J. Comput. Chem. 2011;32:3135–3141. doi: 10.1002/jcc.21886. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 2008;29:1859–1865. doi: 10.1002/jcc.20945. [DOI] [PubMed] [Google Scholar]
- 33.Guvench O, et al. Additive empirical force field for hexopyranose monosaccharides. J Comput Chem. 2008;29:2543–2564. doi: 10.1002/jcc.21004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.MacKerell AD, et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B. 1998;102:3586–3616. doi: 10.1021/jp973084f. [DOI] [PubMed] [Google Scholar]
- 35.MacKerell AD, Jr, Feig M, Brooks CL., 3rd Improved treatment of the protein backbone in empirical force fields. J. Am. Chem. Soc. 2004;126:698–699. doi: 10.1021/ja036959e. [DOI] [PubMed] [Google Scholar]
- 36.Essmann U, et al. A Smooth Particle Mesh Ewald Method. J. Chem. Phys. 1995;103:8577–8593. doi: 10.1063/1.470117. [DOI] [Google Scholar]
- 37.Steinbach PJ, Brooks BR. New Spherical-Cutoff Methods for Long-Range Forces in Macromolecular Simulation. J. Comput. Chem. 1994;15:667–683. doi: 10.1002/jcc.540150702. [DOI] [Google Scholar]
- 38.Brooks BR, et al. CHARMM: the biomolecular simulation program. J. Comput. Chem. 2009;30:1545–1614. doi: 10.1002/jcc.21287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Phillips JC, et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 2005;26:1781–1802. doi: 10.1002/jcc.20289. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Feller SE, Zhang YH, Pastor RW, Brooks BR. Constant-Pressure Molecular-Dynamics Simulation - the Langevin Piston Method. J. Chem. Phys. 1995;103:4613–4621. doi: 10.1063/1.470648. [DOI] [Google Scholar]
- 41.Martyna GJ, Tobias DJ, Klein ML. Constant-Pressure Molecular-Dynamics Algorithms. J. Chem. Phys. 1994;101:4177–4189. doi: 10.1063/1.467468. [DOI] [Google Scholar]
- 42.Shaw DE, et al. Anton, a special-purpose machine for molecular dynamics simulation. Commun. ACM. 2008;51:91–97. doi: 10.1145/1364782.1364802. [DOI] [Google Scholar]
- 43.Shan, Y. B., Klepeis, J. L., Eastwood, M. P., Dror, R. O. & Shaw, D. E. Gaussian split Ewald: A fast Ewald mesh method for molecular simulation. J. Chem. Phys. 122 (2005). [DOI] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.